Responsible by design
Responsible by design
Responsible by design

 

Responsible by design is how SCILEX leads by example. We’re committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most. With a passion for patients and a dedication to innovation, SCILEX is lighting the way forward in pain management.

 
Lighting the way forward
Lighting the way forward
Lighting the way forward

Latest
SCILEX news

SCILEX PHARMACEUTICALS, SORRENTO THERAPEUTICS’ SUBSIDIARY, FILES MARKETING AUTHORIZATION APPLICATION IN THE EUROPEAN UNION FOR ZTLIDO™

FOR IMMEDIATE RELEASE SCILEX PHARMACEUTICALS, Sorrento THERAPEUTICS’ SUBSIDIARY, FILES MARKETING AUTHORIZATION APPLICATION IN THE EUROPEAN UNION FOR ZTlido™   SAN DIEGO, November 14th, 2017 /GlobalNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), announced today that Scilex Pharmaceuticals Inc. (“Scilex”), a majority-owned subsidiary of Sorrento, filed the European Marketing Authorization Application (MAA) for its lead product … Continue reading SCILEX PHARMACEUTICALS, SORRENTO THERAPEUTICS’ SUBSIDIARY, FILES MARKETING AUTHORIZATION APPLICATION IN THE EUROPEAN UNION FOR ZTLIDO™

 

Re-engineering pain management

At SCILEX, we believe that innovation is the path to improving therapeutic outcomes in pain management. We believe our advances in this area are evidence of our tireless dedication to optimizing the patient experience.

X

Share This Page

XS SM MD LG XL